Atossa Therapeutics (ATOS) Prices $50 Million Registered Direct Offering of Common Stock, Warrants

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase $50.0 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $2.88.

Under the terms of the securities purchase agreement, the Company has agreed to sell 17,361,100 shares of the Company’s common stock and issue unregistered warrants to purchase up to an additional 13,020,825 shares of common stock in a concurrent private placement. The warrants have an exercise price of $2.88 per share, are exercisable immediately and will expire four and a half years following the date of issuance.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $50.0 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about March 24, 2021, subject to the satisfaction of customary closing conditions.

You May Also Be Interested In

• Centessa Pharmaceuticals (CNTA) Announces $100 Million Proposed Public Offering of American Depositary Shares
• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Centessa Pharmaceuticals (CNTA) Announces Pricing of $100 Million Public Offering of American Depositary Shares